WASHINGTON, LONDON and HONG KONG, March 17, 2011 /PRNewswire/ —
SuperNova Diagnostics®, Inc., a privately-held global
diagnostics company for human and non-human health applications,
announced today that it has signed an agreement with Shenzhen Kang
Sheng Bao Bio-Technology Co., Ltd. (“KSB”), a biotechnology
diagnostics company specializing in research, manufacture and
distribution of in-vitro diagnostic kits and research reagents in
China and affiliated markets. Financial terms of the
agreement were not disclosed.
“We are delighted to announce this agreement with KSB
Diagnostics, a leader in China and Asia for diagnostics,” said Neil
Campbell, president & CEO of SuperNova Diagnostics. “This
collaborative relationship allows SuperNova and KSB to expand
R&D, manufacturing and commercialisation into one of the
world’s largest markets.”
About AmpCrystal® TechnologyAmpCrystal®, SuperNova
Diagnostics’ lead technology with multiple product formats, allows
for minimally trained individuals (advanced CLIA-waived) to test
for a wide range of protein analytes and can detect directly
un-amplified DNA in humans, animals or environmental samples.
AmpCrystal® is hyper-dense, energy-mediated proprietary
nanocrystals that can be utilised in a wide variety of diagnostic
applications and configurations. The technology platform lends
itself to both forward-integration into new product formats as well
as backward compatible into existing open and closed diagnostic
systems.
Time-to-result has been shown in prototypes to be reduced to
minutes on the spot versus the hours or days required when sending
samples to a central laboratory or processing in regional satellite
laboratories. With three integrated capabilities (sample
collector/processor, analytical disposable, and the readout
device), the technology is simpler, more robust, faster and
significantly less expensive than existing POC systems.
About S
‘/>”/>
